Global markets cheered last week when President Donald Trump pulled back from threats to impose sweeping tariffs on European nations, reaching what he called the "framework of a future deal" on Greenland with NATO Secretary-General Mark Rutte. The sudden about-face revived a familiar trading pattern that Wall Street has labeled with a memorable acronym: TACO, or "Trump Always Chickens Out."

The Pattern of Brinksmanship

The January 21 announcement followed a well-established playbook from Trump's trade policy. Announce aggressive tariffs, watch markets tumble and allies protest, then step back with a deal that falls short of initial threats but can be framed as victory. Markets have learned to anticipate this pattern—and to buy the dip when tariff threats seem most dire.

The Dow Jones Industrial Average surged 588 points (1.21%) on the day of Trump's announcement, closing at 49,007. The S&P 500 gained 1.16%, and the Nasdaq Composite advanced 1.18%. It was one of the strongest single-day rallies of 2026, driven almost entirely by trade-war relief.

"The market response—and the president's retreat—revived talk of the TACO trade. Investors are betting that the bark is worse than the bite when it comes to tariffs."

— CNBC Market Analysis

But Tariffs Remain at Century Highs

The TACO narrative risks oversimplifying a genuinely transformed trade environment. While Trump may back off specific threats, the cumulative effect of his tariff policies has been historic. According to the Tax Policy Center, the average tariff rate on all imports currently stands at 17%—and if all announced policies take effect, that figure would rise to 21%.

For context, the overall average effective U.S. tariff rate rose from 2.5% in early 2025 to an estimated 27% by April 2025—the highest level in over a century. While subsequent negotiations and modifications have brought that down to approximately 16.8%, it still represents a dramatic departure from the near-free-trade consensus that prevailed before Trump's initial term.

The Supreme Court Wild Card

Trump's tariff authority faces a legal challenge that could reshape trade policy. The U.S. Supreme Court is currently evaluating whether the president exceeded his authority under the International Economic Emergency Powers Act (IEEPA) when imposing sweeping tariffs. A ruling is expected in early 2026.

In May 2025, the United States Court of International Trade ruled that Trump had exceeded his authority, finding the IEEPA tariffs "illegal because the triggering emergency (fentanyl trafficking and trade deficits) bore no rational connection to the trade measures imposed." The Supreme Court's decision to take up the case suggests the justices see legitimate constitutional questions worth addressing.

What's Actually in Force

For businesses and consumers navigating the current trade landscape, here's what's currently active:

  • AI chips: A 25% tariff on specific semiconductor categories, particularly those re-exported through third countries, took effect January 15, 2026
  • Taiwan deal: A new agreement lowered Taiwan's reciprocal tariff rate from 20% to 15% as of January 15
  • Iranian oil purchasers: Countries buying Iranian oil face an additional 25% tariff on exports to the United States
  • USMCA review: The Office of the United States Trade Representative has begun the required review of the U.S.-Mexico-Canada Agreement, which must be completed by July 1, 2026

The Pharmaceutical Warning

Perhaps most significant for consumers and healthcare systems, the Trump administration has signaled that tariffs on pharmaceuticals could rise toward 200% by mid-to-late 2026. While this remains a threat rather than implemented policy, it represents the most dramatic potential escalation still on the table.

Drug pricing has been a bipartisan concern, and Trump has framed pharmaceutical tariffs as a way to force companies to manufacture in the United States. Critics argue such tariffs would simply raise prices for American patients while doing little to change manufacturing economics.

Investor Implications

For investors, the TACO trade has been profitable—but it's not without risk. The strategy works until it doesn't, and there's no guarantee that future tariff threats will be walked back before causing real economic damage.

Citadel founder Ken Griffin, speaking at Davos last week, warned that trade uncertainty is weighing on investment decisions across markets: "Investors around the world do not want to see an escalation of the stress of global trade." Corporate capital expenditure decisions, which require long planning horizons, are particularly vulnerable to policy whiplash.

Sectors to Watch

  • Semiconductors: The 25% AI chip tariff creates winners (domestic capacity) and losers (companies dependent on Asian supply chains)
  • Pharmaceuticals: Potential 200% tariffs make healthcare exposure risky until policy clarity emerges
  • Industrials: Companies with North American manufacturing benefit from continued USMCA preferential treatment
  • Retail: Import-dependent consumer goods companies remain vulnerable to tariff escalation

The Bottom Line

Trump's tariff retreat on Europe provided a sugar high for markets, and the TACO trade continues to attract adherents who view trade-war threats as negotiating theater rather than genuine policy intent. But with effective tariff rates still at century highs, a Supreme Court challenge pending, and pharmaceutical tariffs potentially on the horizon, the trade picture is far from settled.

The market's optimism is based on a bet that Trump prioritizes dealmaking over disruption—that he wants wins he can announce rather than prolonged economic warfare. So far, that bet has paid off. But investors should remember that the taco occasionally gets eaten.